Shares of Bicycle Therapeutics (BCYC) are up over 26% to $25.80 on Monday afternoon after the company disclosed in an abstract Sunday that 45% of bladder cancer patients responded to its experimental treatment in an early-stage study, Lei Lei Wu of Endpoints News reports. Bicycle’s experimental treatment would compete with Padcev, which is made by Astellas (ALPMF), Pfizer (PFE) and Merck (MRK).
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCYC:
- RBC starts Bicycle Therapeutics at Outperform on ‘novel and unique platform’
- Bicycle Therapeutics initiated with an Outperform at RBC Capital
- Bicycle Therapeutics downgraded to Neutral from Buy at B. Riley
- Bicycle Therapeutics reports Q2 EPS (77c), consensus ($1.10)
- Bicycle Therapeutics Clears Debt Early, Strengthens Finances